| Followers | 133 |
| Posts | 23021 |
| Boards Moderated | 0 |
| Alias Born | 05/15/2009 |
Friday, October 18, 2024 3:49:20 PM
According to recent updates, the FDA appears to be leaning towards approving Sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs), but with significant concerns regarding antimicrobial resistance and the need for careful monitoring through post-marketing surveillance to ensure appropriate usage; the FDA Advisory Committee acknowledged the potential benefit for a subset of patients while emphasizing the importance of managing off-label use and potential impact on antimicrobial resistance if approved.
Recent ITRM News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 10:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 10:06:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/13/2026 09:30:03 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 02/13/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:30:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/02/2026 10:15:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/23/2025 10:15:04 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 12/17/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2025 10:00:28 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 12/05/2025 01:00:00 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 12:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:15:29 PM
- Iterum Therapeutics Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 • GlobeNewswire Inc. • 11/07/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2025 09:18:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/16/2025 09:16:40 PM
- Iterum Therapeutics to Present Data at IDWeek 2025 • GlobeNewswire Inc. • 10/14/2025 12:30:00 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 09/19/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2025 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2025 08:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 12:15:27 PM
- Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. • GlobeNewswire Inc. • 08/20/2025 12:00:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
